APA (7th ed.) Citation

RB, T., G, S., G, H. E., HM, A., U, S., S, G., . . . K, S. (2026). Observational and Mendelian randomization studies of plasma sclerostin levels do not provide evidence of cardiovascular adverse effects of sclerostin inhibition. Human molecular genetics, 35(2), . https://doi.org/10.1093/hmg/ddaf177

Chicago Style (17th ed.) Citation

RB, Thorolfsdottir, et al. "Observational and Mendelian Randomization Studies of Plasma Sclerostin Levels Do Not Provide Evidence of Cardiovascular Adverse Effects of Sclerostin Inhibition." Human Molecular Genetics 35, no. 2 (2026). https://doi.org/10.1093/hmg/ddaf177.

MLA (9th ed.) Citation

RB, Thorolfsdottir, et al. "Observational and Mendelian Randomization Studies of Plasma Sclerostin Levels Do Not Provide Evidence of Cardiovascular Adverse Effects of Sclerostin Inhibition." Human Molecular Genetics, vol. 35, no. 2, 2026, https://doi.org/10.1093/hmg/ddaf177.